A treatment difference of just 1.38 monthly migraine days sounds modest until you consider who was in the trial: patients who had already failed between one and four preventive therapies, a population for whom even partial relief represents a meaningful clinical advance. That is the number Lundbeck brought to the American Headache Society congress in Orlando this week, reporting that bocunebart — its investigational anti-PACAP monoclonal antibody — met the primary endpoint of the IV arm of the Phase IIb PROCEED trial with a statistically significant separation from placebo (p=0.0178) over 12 weeks.
The PACAP mechanism is the clinically interesting part here. Calcitonin gene-related peptide has been the dominant target in migraine prevention since erenumab launched in 2018, followed quickly by fremanezumab and galcanezumab. Bocunebart works through an entirely separate neuropeptide pathway, which matters because CGRP-class drugs leave a measurable fraction of patients without adequate disease control. Estimates of refractory migraine — those who fail preventive therapies — range from 5–30% of all migraine sufferers, translating to as many as 12 million patients annually in the US alone. PROCEED enrolled specifically from that pool, and the signal held. In the chronic migraine subgroup pooled across the full Phase II program, the treatment difference widened to 2.31 fewer migraine days per month versus placebo among prior treatment failures (p<0.001) — a substantially larger effect than the trial-level headline figure, and the number Lundbeck will want regulators to linger on.
The trial design also produced an instructive failure. The subcutaneous arm triggered a predefined futility rule at interim analysis, redirecting enrollment into the IV arm that ultimately succeeded. That is not a safety story — tolerability was clean, with nasopharyngitis the only adverse event clearing the 5% threshold — but it is a formulation constraint Lundbeck must resolve before pivotal development. Additional Phase I data presented at the same congress showed bocunebart can be co-administered with ubrogepant and, from prior presentations, with triptans, which meaningfully de-risks the combination-use question regulators and payers will raise.
The single variable that will determine bocunebart’s commercial and regulatory trajectory is whether the IV route proves durable across a Phase III program or whether a viable subcutaneous formulation emerges. Every anti-CGRP competitor reached commercial scale via self-administered subcutaneous injection; a chronic IV regimen for migraine prevention faces a different reimbursement and adherence calculus entirely. Watch the route-of-administration disclosure in Lundbeck’s Phase III design announcement — that choice is the trial.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
